Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream

Welsh, Oliverio; Olazarán, Zulema; Gómez, Minerva; Salas, Julio; Berman, Brian

doi:10.1016/j.jaad.2004.04.022

Cited by 54 publications

(49 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 The use of imiquimod is a promising therapeutic option, principally for small to medium-sized lesions that are not excessively deep. 19,20 The two patients (2%) treated with this medication achieved a fast response that resulted in partial cure in the case of the patient with a paranasal lesion and complete cure in the patient with a lesion on his lower eyelid. Local side effects such as inflammation and erythema reported in the literature were also found in this study and required interruption of the medication for 15 days.…”

Section: Discussionmentioning

confidence: 99%

“…15,18 New forms of therapy have been tested, among them a topical immunomodulator, which was evaluated with good results in superficial hemangiomas in the proliferative phase. 19,20 Different types of laser may be used in the management of hemangiomas, including argon, CO2, Nd:YAG and, more recently, long-pulsed tunable dye laser (LPTDL). 15 Embolization is seldom used due to the risk of particle migration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Abordagem terapêutica dos hemangiomas cutâneos na infância

A¹,

Soares²,

Júnior³

et al. 2010

An. Bras. Dermatol.

View full text Add to dashboard Cite

BACKGROUND: Hemangiomas are benign, self-involuting tumors of endothelial cells that are common in childhood. OBJECTIVES: To evaluate the treatment of 122 patients with skin hemangiomas treated at a teaching hospital in Brasilia, Brazil between March 2000 and December 2006. MATERIAL AND METHODS: Data were collected from the patients' medical records and questionnaires were applied to the children's parents. Variables analyzed were: gender, pre-and perinatal factors, clinical characteristics of the lesions, type of treatment and outcome. RESULTS: A male-to-female ratio of 1.5:1 was found. In 42 patients, hemangiomas were superficial, while in 13 cases they were deep and in 67 patients lesions were mixed. In 7 patients, the lesions were associated with syndromes. In 79 patients, hemangiomas were in the cephalic region. Of the 122 patients, 98 were submitted to one single treatment, while 24 required multiple forms of treatment. In the first group, expectant management was the conduct in 38 patients, compression in 3 cases, systemic corticotherapy in 18 patients, intralesional corticotherapy in 13, topical steroids in 4 cases, conventional surgery in 12 patients, cryosurgery in 7, pulsed light in one case and imiquimod in 2 patients. In the second group of 24 patients submitted to multiple treatment modalities, 15 required two types of treatment and 9 needed three or more. CONCLUSIONS: The data obtained in this study were in agreement with results in the literature with respect to gender and the site of the lesions. The incidence of hemangiomas present at birth was higher than rates published in the literature. The therapeutical results obtained were comparable with data from other published studies. Identification of hemangiomas that require treatment, as well as the right moment for intervention and the best therapeutic option for each case, are factors that need to be taken into consideration. Keywords: corticosteroids; combined therapy; cryosurgery; outcome of therapeutic interventions; general surgery; hemangioma; therapeutics Resumo: FUNDAMENTOS: Hemangioma é um tumor benigno de células endoteliais comum na infância e de involução espontânea. OBJETIVO: Avaliar os tratamentos utilizados em 122 pacientes com hemangiomas cutâ-neos, tratados no Hospital Universitário de Brasília, de março de 2000 a dezembro de 2006. MÉTODOS: Utilizou-se coleta de dados em prontuários e aplicação de questionários aos pais. Foram analisados gênero, fatores pré-natais e perinatais, características clínicas, tipo de tratamento e resultados. RESULTADOS: A razão de sexo (F: M) foi de 1,5:1. 42, em pacientes que apresentavam hemangiomas superficiais, 13 profundos e 67 mistos; em 7 pacientes, havia associação com síndromes. Em 79 pacientes, localizavam-se no polo cefálico. Já em 98/122 dos pacientes, foram submetidos a tratamento único e 24/122 a múltiplos. No primeiro grupo, foi utilizada conduta expectante em 38 pacientes, compressão em 3, corticoide sistêmico em 18, corticoide intralesional em 13, corticoide tópico em 4, cir...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Abordagem terapêutica dos hemangiomas cutâneos na infância

A¹,

Soares²,

Júnior³

et al. 2010

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…The drug was applied 3 times a week for the first 4 weeks, followed by 5 times a week until achievement of desired results. This pioneering report was followed by several other case/series reports and trials (20)(21)(22)(23).…”

Section: Timolol Maleatementioning

confidence: 92%

“…imiquimod 3 times per week. In case of unsatisfactory response after 4 weeks, the frequency of application may be increased to 5-7 times a week (20)(21)(22)(23). The average duration of treatment is 16 weeks, but this period may be prolonged or shortened if necessary.…”

Section: Imiquimodmentioning

confidence: 99%

Topical Treatment of Infantile Hemangiomas – Where Are We Now? / Topikalni tretman infantilnih hemangioma – gde smo danas?

Semkova¹,

Marina²,

Kazandjieva³

2011

Serbian Journal of Dermatology and Venerology

View full text Add to dashboard Cite

Infantile hemangiomas are the most common, benign vascular tumors of infancy. Their main feature is spontaneous involution over months to years after an initial phase of rapid proliferation. Small, superficial lesions usually resolve without sequel, but scarring and disfigurement are still possible, while the cosmetic outcome is unpredictable. Thus, inflantile hemangiomas benefit from non-aggressive topical treatment, because it is safe and with an overall outcome comparable to spontaneous involution. The available topical agents reported in the literature to satisfy these requirements are topical beta-blockers, imiquimod and topical corticosteroids. However, none of these have been assessed in randomized controlled trials, and standardized treatment recommendations about precise dosing and patient selection are not available yet.

show abstract

“…Martinez et al 73 reported the successful use of topical imiquimod applied three times a week to treat two patients with infantile hemangiomas. Welsh et al 74 applied topical imiquimod 5% cream five times a week to infantile hemangiomas and achieved complete resolution or excellent improvement in seven out of 10 patients. Hazen et al 75 reported a case report of a chest wall hemangioma that resolved after 10 weeks of topical imiquimod therapy.…”

Section: Hemangiomasmentioning

confidence: 99%

Angiogenesis in cutaneous disease: Part II

Laquer

Hoang

Nguyen

et al. 2009

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

This review will discuss the role of angiogenesis in specific cutaneous diseases. Scientific evidence now points to the role of angiogenesis in tumor development and many other cutaneous disorders. Angiogenesis is a complex process that involves angiogenic growth factors and inhibitors, many of which could be a potential target for pharmacologic intervention. Antiangiogenic agents have recently been applied to dermatologic diseases with promising efficacy. ( J Am Acad Dermatol 2009;61:945-58.)Learning objectives: After completing this learning activity, participants should be able to recognize cutaneous diseases where angiogenesis is likely to be an important factor, recognize scenarios where angiogenic therapy may be useful in conjunction with traditional therapies, and be able to use angiogenicmediating agents in the treatment of dermatologic disease.

show abstract

Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream

Cited by 54 publications

References 11 publications

Abordagem terapêutica dos hemangiomas cutâneos na infância

Abordagem terapêutica dos hemangiomas cutâneos na infância

Topical Treatment of Infantile Hemangiomas – Where Are We Now? / Topikalni tretman infantilnih hemangioma – gde smo danas?

Angiogenesis in cutaneous disease: Part II

Contact Info

Product

Resources

About